Myocardial infarction (MI) frequently recurs after non-ST elevation MI (NSTEMI) that may be related to insufficient vulnerable plaque identification using invasive coronary angiography. Furthermore, the natural behaviour of vulnerable plaques in NSTEMI over time and their relation with biomarkers need further exploration. More accurate identification and assessing long-term behaviour of vulnerable plaques may improve therapeutic strategies and clinical outcome. The investigators hypothesize that fully integrated 18Fluoride Sodium-Fluoride (18F-NaF) Positron Emission Tomography/Cardiac Magnetic Resonance imaging (PET/CMR) increases the ability to detect vulnerable plaques as compared to coronary angiography. This prospective study in 33 consecutive patients with NSTEMI aims to: 1. Compare coronary vulnerable plaque detection between 18F-NaF PET/CMR and invasive coronary angiography, 2. Investigate the correlation of coronary vulnerable plaques using 18F-NaF PET with myocardial infarction using CMR, both at baseline and during follow-up, 3. Examine systemic arterial 18F-NaF-uptake using PET/CMR and their relation with systemic events (cerebrovascular accidents, transient ischemic attacks, or peripheral arterial disease), and 4. Examine the relation between vulnerable plaques and plasma biomarkers.
Study Type
OBSERVATIONAL
Enrollment
10
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
The frequency of coronary vulnerable plaques in non-ST-elevation myocardial infarction (NSTEMI) using 18Fluoride Sodium-Fluoride (18F-NaF) Positron Emission Tomography/Cardiac Magnetic Resonance (PET/CMR).
Time frame: 0 to 6 months
The frequency of coronary vulnerable plaques in NSTEMI using routine invasive coronary angiography.
Time frame: 0 to 6 months
The location of vulnerable plaques within the coronary arteries using 18F-NaF PET at baseline and follow-up.
Time frame: 0 to 6 months
Based on the AHA 17-segment model, the segmental location of MI using CMR at baseline and follow-up.
Time frame: 0 to 6 months
The frequency of systemic vulnerable plaques as assessed with 18F-NaF PET/CMR at baseline and follow-up.
Time frame: 0 to 6 months
Serial serum concentrations of biomarkers of plaque vulnerability and myocardial injury at baseline and follow-up.
Time frame: 0 to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.